ANR — Anatara Lifesciences Income Statement
0.000.00%
Last trade - 00:00- AU$10.70m
- AU$9.72m
Annual income statement for Anatara Lifesciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3.42 | 2 | 2.53 | 2.04 | 1.46 |
| Operating Profit | -3.42 | -2 | -2.53 | -2.04 | -1.46 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -3.36 | -2 | -2.53 | -2.02 | -1.45 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.36 | -2 | -2.53 | -2.02 | -1.45 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.36 | -2 | -2.53 | -2.02 | -1.45 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.36 | -2 | -2.53 | -2.02 | -1.45 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.063 | -0.029 | -0.032 | -0.019 | -0.01 |